OpenAI's annualized revenue aims for $70 billions, with enterprise business as a driving force
According to sources familiar with the matter, OpenAI is expected to reach or exceed an annualized revenue of 7 billion dollars by the end of this year, mainly driven by the growth of its enterprise business.
According to information obtained by Zhihu Finance APP, OpenAI is expected to reach or exceed an annualized revenue of $70 billion by the end of this year, primarily driven by enterprise business growth. These sources said that as of the end of September, the ChatGPT developer's annualized revenue was about $50 billion. This figure is based on projections from a shorter period of OpenAI’s annual sales.
The sources indicated that the company shared these figures with investors during discussions for the latest round of financing. In September, it was first reported that OpenAI was in talks to raise $30 billion or more with a pre-money valuation of $1.4 trillion.
OpenAI, Anthropic, and other AI companies often promote annualized revenue as a key growth metric. However, not all companies use the same method for calculation. According to earlier reports, Anthropic's annualized revenue reached $65 billion as of the end of July.
Some media reported last month that, based on investors’ estimates, OpenAI was expected to have annualized revenue close to $70 billion. It was reported on Thursday that this discrepancy arose because OpenAI's investors tried to use the same method as competitor Anthropic PBC to calculate OpenAI’s annualized revenue, whereas Anthropic treats the sales to cloud service providers differently.
On Thursday, after reports that OpenAI's annualized revenue would be below some previous estimates, tech stocks led the decline in the S&P 500 index. The Nasdaq 100 index fell 1.4%, and the semiconductor giant index dropped 3.4%.
Although OpenAI has postponed its IPO plans until at least next year, citing a focus on AI safety, Anthropic is expected to sell shares in an IPO as early as November.
It is reported that OpenAI is negotiating with several investment funds from the United Arab Emirates, including MGX, which is headquartered in Abu Dhabi, to help anchor its new funding round.
The company recently completed a $122 billion round of financing in March, bringing its valuation to $852 billion including this capital.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - RBC expects gradual improvement in North American and European building materials stocks in the third quarter
October 9 - RBC expects the performance of most European building material products to gradually improve quarter-on-quarter in Q3, but notes that geopolitical uncertainties in the US will continue to drive up cost inflation and increase market volatility. RBC anticipates that sales in Europe will remain sluggish due to heatwaves and rising mortgage rates, while a weak US housing market and the lack of a significant hurricane season will prompt roofing material companies to enter a destocking cycle. The firm is more optimistic about Germany’s Heidelberg Group (HEIG.DE), upgrading its rating to “outperform,” and points out that the company has handled the challenging quarter caused by extreme weather far better than its peers. Due to severe cost headwinds such as rising diesel and natural gas prices, RBC downgraded the ratings of US and French construction companies Knife River (KNF.N) and Saint-Gobain (SGOB.PA) from “outperform” to “market perform.” (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them solely for the ease of the reader. Reuters assumes no liability for any damages or losses that may arise from the use of automated translation functions.)
3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million
Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
Crypto prices
More
